Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

893
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
893
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

203
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
203
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

492
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
492
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

148
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
148

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute Low Back Pain: Diagnosis and Management.

American family physician·2025
Same author

Piroxicam Plus Plan B for Emergency Contraception.

Journal of the American Board of Family Medicine : JABFM·2025
Same author

Just Pop It: Early AROM After Cervical Ripening Reduces the Time to Delivery.

Journal of the American Board of Family Medicine : JABFM·2024
Same author

Diabetic Myonecrosis of the Axilla: A Novel Case With Severe Clinical Features.

Cureus·2023
Same author

Which anticoagulant is safest for frail elderly patients with nonvalvular A-fib?

The Journal of family practice·2022
Same author

No pain, if you've got game.

The Journal of family practice·2021

Related Experiment Video

Updated: Dec 1, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.1K

PURL:Rethinking daily aspirin for primary prevention.

Michael Poplawski1, Nicole K Nelson1, J Scott Earwood1

  • 1Dwight D. Eisenhower Army Medical Center, Fort Gordon, GA, USA.

The Journal of Family Practice
|November 11, 2020
PubMed
Summary

Aspirin use in individuals without cardiovascular disease is clarified by a new meta-analysis. Newer randomized controlled trials (RCTs) suggest aspirin is not recommended for primary prevention.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.7K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.5K

Related Experiment Videos

Last Updated: Dec 1, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.1K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.7K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.5K

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Clinical Trials

Background:

  • Aspirin is widely used for secondary prevention of cardiovascular events.
  • Its role in primary prevention for individuals without established atherosclerotic cardiovascular disease (CVD) remains debated.

Purpose of the Study:

  • To evaluate the efficacy and safety of aspirin for primary prevention of atherosclerotic CVD.
  • To provide updated evidence based on recent randomized controlled trials (RCTs).

Main Methods:

  • Systematic review and meta-analysis of recent RCTs.
  • Inclusion of studies focusing on individuals without a history of atherosclerotic CVD.
  • Assessment of cardiovascular events, bleeding events, and all-cause mortality.

Main Results:

  • The meta-analysis indicates no significant reduction in major adverse cardiovascular events with aspirin use for primary prevention.
  • An increased risk of gastrointestinal bleeding and other hemorrhagic events was observed.
  • No significant benefit in reducing all-cause mortality was found.

Conclusions:

  • Current evidence from updated RCTs does not support the routine use of aspirin for primary prevention of atherosclerotic CVD.
  • The potential harms, particularly bleeding risks, outweigh the uncertain benefits in this population.
  • Clinical guidelines should be updated to reflect these findings, discouraging aspirin use in individuals without established CVD.